Molecular antigen array 机翻标题: 暂无翻译,请尝试点击翻译按钮。

公开号/公开日
US2003054010 A1 2003-03-20 [US20030054010]US6964769 B2 2005-11-15 [US6964769] / 2003-03-202005-11-15
申请号/申请日
2001US-09848616 / 2001-05-04
发明人
SEBBEL PETER;DUNANT NICOLAS;BACHMANN MARTIN;TISSOT ALAIN;LECHNER FRANZISKA;RENNER WOLFGANG A;HENNECKE FRANK;NIEBA LARS;
申请人
CYTOS BIOTECHNOLOGY ZURICH SCHLIEREN;
主分类号
IPC分类号
A61K-038/00A61K-039/385A61P-031/00A61P-035/00A61P-037/00A61P-037/08C07K-014/245C12N-015/30C12N-015/31C12N-015/33C12N-015/51
摘要
(US6964769) The invention provides compositions and processes for the production of ordered and repetitive antigen or antigenic determinant arrays.  The compositions of the invention are useful for the production of vaccines for the prevention of infectious diseases, the treatment of allergies and the treatment of cancers.  Various embodiments of the invention provide for a core particle that is coated with any desired antigen in a highly ordered and repetitive fashion as the result of specific interactions.
机翻摘要
暂无翻译结果,您可以尝试点击头部的翻译按钮。
地址
代理人
代理机构
;
优先权号
2000US-60202341 2000-05-05 2001US-09848616 2001-05-04
主权利要求
(US6964769) 1. A composition comprising:     (a) a non-natural molecular scaffold comprising:  (i) a virus-like particle that is a dimer or a multimer of a polypeptide comprising, as a core particle, a polypeptide having the amino acid sequence of SEQ ID NO:158, modified such that the cysteine residues at positions 48 and 110 of SEQ ID NO:158 (corresponding to positions 48 and 107 of SEQ ID NO:134) are either deleted or substituted with another amino acid, or a sequence having at least 90% sequence identity to said polypeptide sequence and in which the cysteine residues at positions 48 and 110 of SEQ ID NO:158 are either deleted or substituted with another amino acid;    and (ii) an organizer comprising at least one first attachment site, wherein said organizer is connected to said core particle by at least one covalent bond;    and (b) an antigen or antigenic determinant with at least one second attachment site, said second attachment site being selected from the group consisting of:  (i) an attachment site not naturally occurring with said antigen or antigenic determinant;    and (ii) an attachment site naturally occurring with said antigen or antigenic determinant, wherein said second attachment site is capable of association through at least one non-peptide bond to said first attachment site;  and wherein said antigen or antigenic determinant and said scaffold interact through said association to form an ordered and repetitive antigen array. 2. The composition of claim 1, wherein said organizer is a polypeptide or residue thereof;  and wherein said second attachment site is a polypeptide or residue thereof. 3. The composition of claim 1, wherein said first and/or said second attachment sites comprise:     (a) an antigen and an antibody or antibody fragment thereto;    (b) biotin and avidin;    (c) strepavidin and biotin;    (d) a receptor and its ligand;    (e) a ligand-binding protein and its ligand;    (f) interacting leucine zipper polypeptides;    (g) an amino group and a chemical group reactive thereto;    (h) a carboxyl group and a chemical group reactive thereto;    (i) a sulfhydryl group and a chemical group reactive thereto;  or (j) a combination thereof. 4. The composition of claim 3, wherein said first attachment site is an amino group and said second attachment site is a sulfhydryl group. 5. The composition of claim 1, wherein said antigen or antigenic determinant is selected from the group consisting of:     (a) an antigen suited to induce an immune response against bacteria;    (b) an antigen suited to induce an immune response against viruses;    (c) an antigen suited to induce an immune response against parasites;    (d) an antigen suited to induce an immune response against cancer cells;    (e) an antigen suited to induce an immune response against allergens;    (f) an antigen suited to induce an immune response in a farm animals;    and (g) a protein suited to induce an immune response in a pet. 6. The composition of claim 5, wherein the antigen or antigenic determinant is a protein, polypeptide, or a fragment thereof. 7. The composition of claim 5, wherein said antigen or antigenic determinant induces an immune response against one or more allergens. 8. The composition of claim 5, wherein said antigen or antigenic determinant is selected from the group consisting of:     (a) a recombinant protein of HIV;    (b) a recombinant protein of Influenza virus;    (c) a recombinant protein of Hepatitis C virus;    (d) a recombinant protein of Toxoplasma;    (e) a recombinant protein of Plasmodium falciparum;    (f) a recombinant protein of Plasmodium vivax;    (g) a recombinant protein of Plasmodium ovale;    (h) a recombinant protein of Plasmodium malariae;    (i) a recombinant protein of breast cancer cells;    (j) a recombinant protein of kidney cancer cells;    (k) a recombinant protein of prostate cancer cells;    (l) a recombinant protein of skin cancer cells;    (m) a recombinant protein of brain cancer cells;    (n) a recombinant protein of leukemia cells;    (o) a recombinant protein of bee sting allergy;    (p) a recombinant protein of nut allergy;    (q) a recombinant protein of food allergies;    (r) a recombinant protein of asthma;    and (s) a recombinant protein of Chlamydia. 9. A pharmaceutical composition comprising the composition of claim 1, and a pharmaceutically acceptable carrier. 10. An immunogenic composition comprising the composition of claim 1. 11. The immunogenic composition of claim 10, further comprising at least one adjuvant. 12. A method of immunizing, comprising administering to a subject the immunogenic composition of claim 10. 13. The method of claim 12, wherein said administering produces an immune response. 14. The method of claim 13, wherein said administering produces a humoral immune response. 15. The method of claim 13, wherein said administering produces a cellular immune response. 16. The method of claim 13, wherein said administering produces a humoral immune response and a cellular immune response. 17. The method of claim 13, wherein said administering produces a protective immune response. 18. A method of making the composition of claim 1, comprising combining said non-natural molecular scaffold and said antigen or antigenic determinant, wherein said non-natural molecular scaffold and said antigen or antigenic determinant interact to form an antigen array. 19. The method of claim 18, wherein said antigen array is ordered and/or repetitive. 20. A method of immunizing, comprising administering the composition of claim 1, or the immunogenic composition of claim 10, to a subject, wherein said administering produces a Th2 response that is specific for said antigen or antigenic determinant. 21. The method of claim 20, wherein antibodies specific for said antigen or antigenic determinant of a subtype corresponding to the Th2 subtype are induced in the subject. 22. The method of claim 20, wherein the subject does not generate a Th1 response that is specific for said antigen or antigenic determinant. 23. A vaccine composition comprising the composition of claim 1. 24. The vaccine composition of claim 23, further comprising at least one adjuvant.
法律状态
(US6964769) LEGAL DETAILS FOR US2003054010  Actual or expected expiration date=2009-12-14    Legal state=DEAD    Status=LAPSED     Event publication date=2001-05-04  Event code=US/APP  Event indicator=Pos  Event type=Examination events  Application details  Application country=US US09848616  Application date=2001-05-04  Standardized application number=2001US-09848616     Event publication date=2001-05-04  Event code=US/EXMR  Event type=Administrative notifications  USPTO Examiner Name Primary Examiner: MOSHER, MARY    Event publication date=2001-05-04  Event code=US/ART  Event type=Administrative notifications  USPTO Art Group  ART=1648     Event publication date=2001-05-04  Event code=US/ENT  Event type=Administrative notifications  Entity Status Set to Undiscounted Business Entity Status: UNDISCOUNTED    Event publication date=2001-05-04  Event code=US/AIA  Event type=Administrative notifications  First Inventor File Indicated:  AIA=No     Event publication date=2001-05-04  Event code=US/DK  Event type=Examination events  Attorney Docket Number Docket Nbr: 1700.0180002/JAG/BJD    Event publication date=2001-05-04  Event code=US/CUST  Event type=Examination events  Attorney/Agent Customer Number Customer Nbr: 28393    Event publication date=2001-06-14  Event code=US/INCD  Event type=Examination events  Event type=OAO  Notice Mailed--Application Incomplete--Filing Date Assigned    Event publication date=2002-01-14  Event code=US/FPAFF  Event type=Payment or non-payment notifications  Payment of additional filing fee/Preexam    Event publication date=2002-03-09  Event code=US/DOCK  Event indicator=Pos  Event type=Examination events  Case Docketed to Examiner    Event publication date=2002-05-09  Event code=US/IDS  Event type=Examination events  Event type=OAI  Information Disclosure Statement Filed    Event publication date=2002-08-29  Event code=US/AS  Event type=Change of name or address  Event type=Reassignment  Assignment Owner: CYTOS BIOTECHNOLOGY AG, SWITZERLAND ASSIGNMENT OF ASSIGNORS INTEREST ASSIGNORS:SEBBEL, PETER DUNANT, NICOLAS BACHMANN, MARTIN AND OTHERS REEL/FRAME:013037/0095 SIGNING DATES FROM 20020530 TO 20020617     Event publication date=2002-08-29  Event code=US/RESTREQ  Event type=Examination events  Event type=Corrections  Event type=OAO  Restriction/Election Requirement    Event publication date=2002-11-27  Event code=US/ELC  Event type=Examination events  Event type=OAI  Response to Election / Restriction Filed    Event publication date=2002-11-27  Event code=US/136G  Event type=OAO  Request for Extension of Time - Granted    Event publication date=2003-02-06  Event code=US/CTNF  Event type=Examination events  Event type=OA  Event type=OAO  Non-Final Rejection    Event publication date=2003-03-20  Event code=US/A1  Event type=Examination events  Application published  Publication country=US  Publication number=US2003054010  Publication stage Code=A1  Publication date=2003-03-20  Standardized publication number=US20030054010     Event publication date=2003-08-07  Event code=US/CTNFR  Event type=Examination events  Event type=OAI  Response after Non-Final Action    Event publication date=2003-08-07  Event code=US/136G  Event type=OAO  Request for Extension of Time - Granted    Event publication date=2003-10-30  Event code=US/CTFR  Event type=Examination events  Event type=OA  Event type=OAO  Final Rejection    Event publication date=2004-04-29  Event code=US/RCEX  Event type=Examination events  Event type=RCE  Event type=OAI  Request for Continued Examination (RCE)    Event publication date=2004-04-29  Event code=US/136G  Event type=OAO  Request for Extension of Time - Granted    Event publication date=2004-05-12  Event code=US/DRCECAP  Event type=RCE  Event type=OAO  Disposal for a RCE / CPA / R129    Event publication date=2004-07-15  Event code=US/IDS  Event type=Examination events  Event type=OAI  Information Disclosure Statement Filed    Event publication date=2004-07-21  Event code=US/CTNF  Event type=Examination events  Event type=OA  Event type=OAO  Non-Final Rejection    Event publication date=2004-12-21  Event code=US/DC  Event indicator=Neg  Event type=Examination events  Terminal Disclaimer Filed    Event publication date=2004-12-21  Event code=US/CTNFR  Event type=Examination events  Event type=OAI  Response after Non-Final Action    Event publication date=2004-12-21  Event code=US/136G  Event type=OAO  Request for Extension of Time - Granted    Event publication date=2005-02-25  Event code=US/DOCK  Event indicator=Pos  Event type=Examination events  Case Docketed to Examiner    Event publication date=2005-02-28  Event code=US/NOAM  Event indicator=Pos  Event type=Examination events  Event type=OAO  Mail Notice of Allowance    Event publication date=2005-05-23  Event code=US/ENT  Event type=Administrative notifications  Entity Status Set to Undiscounted    Event publication date=2005-10-01  Event code=US/APRDY  Event indicator=Pos  Event type=Examination events  Application Is Considered Ready for Issue    Event publication date=2005-10-26  Event code=US/ISSM  Event indicator=Pos  Event type=Examination events  Event type=OAO  Event type=Restitution or restoration  Issue Notification Mailed    Event publication date=2005-11-15  Event code=US/B2  Event indicator=Pos  Event type=Event indicating In Force  Granted patent as second publication  Publication country=US  Publication number=US6964769  Publication stage Code=B2  Publication date=2005-11-15  Standardized publication number=US6964769     Event publication date=2005-11-15  Event code=US/354  Event indicator=Pos  Event type=Extension of term of duration of protection  Patent term extended under  35 U.S.C 154(b) until/for Delays (A,B,C): 110  Overlap Delays: 0  Non Overlap Delays: 110   PTO Office Delays: 0  Applicant Delays: 363  Adjustment total:  Number of days of extension=0    Event publication date=2008-11-25  Event code=US/NMFP  Event type=Payment or non-payment notifications  Publication of First Notice of Maintenance Fees Payable. PAYMENT NOTICE YEAR:  Year of payment of annual fees=3     Event publication date=2009-05-25  Event code=US/REMI  Event type=Administrative notifications  Maintenance fee reminder mailed    Event publication date=2009-11-15  Event code=US/LAPS  Event indicator=Neg  Event type=Event indicating Not In Force  Event type=Payment or non-payment notifications  Lapse for failure to pay maintenance fees    Event publication date=2009-11-15  Event code=US/FP  Event indicator=Neg  Event type=Event indicating Not In Force  Event type=Payment or non-payment notifications  Expired due to failure to pay maintenance fee  Effective date of the event=2009-11-15     Event publication date=2009-12-14  Event code=US/FP  Event indicator=Neg  Event type=Event indicating Not In Force  Event type=Payment or non-payment notifications  Expired due to failure to pay maintenance fee    Event publication date=2009-12-14  Event code=US/EXP  Event indicator=Neg  Event type=Event indicating Not In Force  Patent expired    Event publication date=2012-11-27  Event code=US/NMFP  Event type=Payment or non-payment notifications  Publication of First Notice of Maintenance Fees Payable. PAYMENT NOTICE YEAR:  Year of payment of annual fees=7     Event publication date=2016-11-29  Event code=US/NMFP  Event type=Payment or non-payment notifications  Publication of First Notice of Maintenance Fees Payable. PAYMENT NOTICE YEAR:  Year of payment of annual fees=11
专利类型码
A1B2
国别省市代码
若您需要申请原文,请登录。

最新评论

暂无评论。

登录后可以发表评论

意见反馈
返回顶部